GrifolsGRFS -1.23%82 Debt-to-EBITDA is 6.85 as of Mar. 2026, which is 32% above its 10-year median of 5.18. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.90 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 687 Drug Manufacturers companies, Grifols ranks worse than 85.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Grifols's Debt-to-EBITDA or its related term are showing as below:
GRFS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 5.18 Max: 9.88
Current: 6.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Grifols was 9.88. The lowest was 0.01. And the median was 5.18.
GRFS's Debt-to-EBITDA is ranked worse than 85.15% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.66
vs GRFS: 6.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Grifols Debt-to-EBITDA Related Terms
Grifols Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Grifols's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Grifols's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grifols's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Grifols (GRFS) has a Debt-to-EBITDA of 6.85 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grifols. This is 32% above median its historical median of 5.18. Over the past decade, Grifols' Debt-to-EBITDA has ranged from 0.01 to 9.88. According to the industry distribution chart, Grifols ranks #585 out of 687 companies in the Drug Manufacturers industry, placing it in the top 85.2%.
Is Grifols' Debt-to-EBITDA too high?
Grifols' current Debt-to-EBITDA of 6.85 is 32% above median its 10-year median of 5.18. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 9.88. The Drug Manufacturers industry median Debt-to-EBITDA is 1.66. Grifols' value of 6.85 is 312.7% above this industry median. Based on the distribution chart, Grifols ranks #585 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #585 out of 687 companies for Debt-to-EBITDA. This places Grifols in the lower half of its industry. The industry median Debt-to-EBITDA is 1.66. Grifols' value of 6.85 is 312.7% above this benchmark. Historically, Grifols' own Debt-to-EBITDA has ranged from 0.01 to 9.88 over the past decade. While the company's 10-year median is 5.18 vs. the industry median of 1.66, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Debt-to-EBITDA of 6.85 is 312.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grifols. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Debt-to-EBITDA is 6.85, which is 32% above median its own 10-year median of 5.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.90, compared to a current price of $7.22 — trading 18.9% below its estimated fair value. The current Debt-to-EBITDA is 6.85, which is 32% above median its 10-year median of 5.18 and 312.7% above the Drug Manufacturers industry median of 1.66. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Grifols (GRFS), the current Debt-to-EBITDA is 6.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.22 is trading 18.9% below its estimated GF Value™ of $8.90.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
Debt-to-EBITDA: 6.85 (32% above median its 10-year median of 5.18)
GF Value™: $8.90 vs. price of $7.22 (18.9% below fair value)
Industry Position: 312.7% above the Drug Manufacturers median (#585 of 687)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score
Get the complete analysis for GRFS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
